Free Cash Flow per Share: A measure of financial performance calculated as operating cash flow minus capital expenditures, expressed on a per share basis. Calculated as: Free Cash Flow / Weighted Average Shares Outstanding (Diluted)
CRISPR Therapeutics AG (CRSP) had Free Cash Flow per Share of $-2.77 for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
$0.89M |
|
$-106.44M |
|
-- |
|
$0.89M |
|
$132.95M |
|
$-132.06M |
|
$26.24M |
|
$-105.82M |
|
$-105.82M |
|
$-106.44M |
|
$-106.44M |
|
$-106.44M |
|
$-106.44M |
|
$-132.06M |
|
$-127.63M |
|
91.31M |
|
91.31M |
|
$-1.17 |
|
$-1.17 |
|
| Balance Sheet Financials | |
$1.93B |
|
$120.83M |
|
$316.22M |
|
$2.25B |
|
$118.96M |
|
-- |
|
$210.37M |
|
$329.33M |
|
$1.92B |
|
$1.92B |
|
$1.92B |
|
93.87M |
|
| Cash Flow Statement Financials | |
$-252.46M |
|
$-69.00M |
|
$309.61M |
|
$309.78M |
|
$298.02M |
|
$-11.76M |
|
$54.42M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
16.22 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-14854.78% |
|
-14854.78% |
|
-- |
|
-11903.49% |
|
-11973.12% |
|
$-252.86M |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
-- |
|
-- |
|
-- |
|
-5.56% |
|
-5.56% |
|
-4.74% |
|
-5.56% |
|
$20.41 |
|
|
Free Cash Flow per Share |
$-2.77 |
$-2.77 |
|